Kyowa Kirin to Present X-linked Hypophosphatemia Research at ASBMR Annual Meeting

Kyowa Kirin Co., Ltd. is set to present groundbreaking new research on the use of burosumab in treating X-linked hypophosphatemia (XLH) at the American Society for Bone and Mineral Research (ASBMR) 2024 annual meeting in Toronto from September 27-30. This rare genetic metabolic bone disease imposes a significant burden on patients, and the findings aim to shed light on real-world experiences and the impact of burosumab treatment.

Kyowa Kirin will deliver an oral presentation by Dr. Judith Bubbear from the Royal National Orthopaedic Hospital, UK, titled "Patient reported outcomes (PRO) from a real-world study of burosumab treatment in adults with X-linked hypophosphatemia in the UK" on September 28. This presentation is expected to offer valuable insights into how burosumab affects the daily lives of adult XLH patients.

Angela Williams, PhD, Vice President and Global Head of Health Economics and Outcomes Research at Kyowa Kirin, emphasized the importance of real-world evidence in understanding XLH and developing effective management strategies. The array of data presented at ASBMR represents Kyowa Kirin's ongoing commitment to advancing the science behind XLH and enhancing the quality of life for those affected by the disease.

Several poster presentations will provide additional insights into the real-world impact of burosumab. Among these, Dr. Pablo Florenzano from Pontificia Universidad Católica de Chile will present on the effectiveness of burosumab compared to conventional therapy in adults. Dr. Leanne M. Ward from the Children's Hospital of Eastern Ontario will discuss biochemical measurements in burosumab-treated patients, while Dr. Vrinda Saraff from Birmingham Women's and Children's Hospital will explore symptoms experienced by adolescents undergoing burosumab treatment.

Other important posters include studies by Dr. Wei Liu from Peking Union Medical College Hospital and Dr. Xiaoping Luo from Tongji Medical College, focusing on the efficacy and safety of burosumab in both adult and pediatric Chinese patients with XLH.

The burden of XLH on various aspects of patients' lives will also be addressed. Dr. Angela Williams will lead an exploratory analysis on the association between pain medication use and patient-reported outcomes, and Dr. Signe Sparre Beck-Nielsen from Aarhus University Hospital will present a retrospective Danish register study on hereditary hypophosphatemia and co-morbidities. Dr. Jill Simmons from Vanderbilt University Medical Center will discuss findings from the XLH Community Impact Survey on psychosocial health, symptoms, and self-care.

To bridge evidence gaps and improve clinical decision-making in XLH, Dr. Maria Luisa Brandi from FIRMO Foundation and University Vita-Salute San Raffaele will present on the rationale and design of the Advancing Patient Evidence in XLH (APEX) global data unification program.

XLH is a rare, lifelong genetic disorder that affects bone and muscle health in both children and adults. It causes the body to excrete too much phosphorus, leading to bone softening and weakening. Symptoms in children include bowed legs or knock knees and delayed growth, while adults may experience osteomalacia and fractures.

CRYSVITA® (burosumab-twza) is a recombinant monoclonal antibody developed by Kyowa Kirin to inhibit the activity of fibroblast growth factor 23 (FGF23), the underlying cause of hypophosphatemia in XLH. By blocking FGF23, CRYSVITA aids in restoring phosphorus levels in the body and promoting bone health.

CRYSVITA is approved for treating XLH in patients aged six months and older. However, it is contraindicated in conjunction with oral phosphate and active vitamin D analogs, and in patients with severe renal impairment, due to risks such as hyperphosphatemia and nephrocalcinosis. Common adverse effects include hypersensitivity reactions, injection site reactions, and various other symptoms like headache and back pain.

Kyowa Kirin's extensive research and development efforts are driven by their commitment to discovering innovative treatments for diseases with unmet medical needs. Their work in XLH and other rare diseases reflects a dedication to improving patient outcomes and advancing medical science.